Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

Newswire.ca - Mon Mar 6, 2023

-  Both the NODE-303 and RAPID-extension studies are complete

-  Following FDA feedback, Etripamil NDA is on-track for submission in the third quarter of 2023

Read more at newswire.ca

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).